In focus · trending topic

Adzenys XR-ODT

40 stories · following the connections

Neos Therapeutics to Present at the Stifel 2017 Healthcare Conference

By Nasdaq OMXNov 7, 2017, 1:00 PM UTC

Neos Therapeutics to Host Third Quarter 2017 Financial Results Conference Call on November 8, 2017

By Nasdaq OMXNov 2, 2017, 12:00 PM UTC

Neos Therapeutics to Present Two Posters on Company’s ADHD Medications at the American Academy of Child & Adolescent Psychiatry Meeting

By Nasdaq OMXOct 24, 2017, 8:21 PM UTC

Neos Therapeutics Announces Settlement with Actavis on Adzenys XR-ODT® Patent Litigation

By Nasdaq OMXOct 18, 2017, 12:00 PM UTC

Neos Therapeutics Announces US Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

By Nasdaq OMXOct 2, 2017, 12:01 PM UTC

Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older

By Nasdaq OMXSep 15, 2017, 8:39 PM UTC

Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

By Nasdaq OMXSep 5, 2017, 12:00 PM UTC

Neos Therapeutics to Participate in Three September Conferences

By Nasdaq OMXAug 30, 2017, 11:30 AM UTC